Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: Initial Australian experience

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 3, 1999, Pages 385-386

  Spencer, A ^b   Firkin, F ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AI LING NO 1; AMSACRINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; RETINOIC ACID; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANKLE EDEMA; ARTICLE; AUSTRALIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; DRUG RESPONSE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRURITUS; TREATMENT OUTCOME;

EID: 0033067396     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb00731.x     Document Type: Article

References (14)

1. 1. Kakizuka A, Miller WH Jr, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-74.
2. 2. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-84.
3. 3. Castaigne S, Balitrand N, de The H, Dejean A, Degos L, Chomienne C. A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79: 3110-5.
4. 4. Huang ME, Ye YC, Chen SR et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chinese Med J 1987; 100: 949-53.
5. 5. Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
6. 6. Ohashi H, Ichikawa A, Takagi N et al. Remission induction of acute promyelocytic leukemia by all-transretinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. Leukemia 1992; 6: 859-62.
7. 7. Fenaux P, Le Deley MC, Castaigne S et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-9.
8. 8. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-8.
9. 9. Thomas X, Anglaret B, Thiebaut A et al. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy. Ann Hematol 1997; 75: 195-200.
10. 10. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997; 90: 1321-5.
11. 11. Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-60.
12. 12. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-8.
13. 13. Huang SY, Chang CS, Tang JL et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998; 103: 1092-5.
14. 14. Chen GQ, Shi XG, Tang W et al. Use of arsenic trioxide (As 203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-53.